Donclair Brown
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Donclair Brown has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Aladin Altic
Department of Internal Medicine, Albert Einstein College of Medicine, Jacobi Medical Center/North Central Bronx Hospital, New York, NY 10467, USA
1 shared publication - Ali Al Zuwayny
Richmond University Medical Center, Staten Island, NY 10310, USA
1 shared publication - James M. Tauras
Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA
1 shared publication - Vishakha Modak
Jacobi Medical Center, Albert Einstein College of Medicine, NYC Health and Hospitals, Bronx, NY 10461, USA
1 shared publication
Latest Publications
- Open Access
- 12 May 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (5) , 205
Transthyretin and Vitamin A Metabolism: A Review for the Cardiac Amyloidosis Specialist
Transthyretin (TTR) amyloidosis is a systemic, progressive, and fatal disease. TTR is integral in vitamin A (retinol) transport via its binding to retinol binding protein 4 (RBP4). Current and emerging therapies for TTR amyloid cardiomyopathy (ATTR-CM), including RNAi therapies and potentially CRISPR-based therapies, reduce hepatic transthyretin production and hence decrease serum RBP4, which decreases circulating vitamin A levels. However, despite these reductions in circulating vitamin A, hepatic reserves and alternative delivery mechanisms may prevent clinical manifestations of vitamin A deficiency. Vitamin A functions as a key regulator of immunity, antioxidant function, cell growth and differentiation and vision. This paper aims to serve as a comprehensive review of vitamin A and its metabolites, their transport, and their function in human health and disease. Additionally, we seek to synthesize the relevant outcomes and safety data of TTR silencing therapies and how they relate to circulating vitamin A levels and vitamin A-related clinical outcomes in a manner that is relevant to the cardiac amyloidosis specialist.
- 12 May 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (5) , 205
Open AccessTransthyretin and Vitamin A Metabolism: A Review for the Cardiac Amyloidosis Specialist
Transthyretin (TTR) amyloidosis is a systemic, progressive, and fatal disease. TTR is integral in vitamin A (retinol) transport via its binding to retinol binding protein 4 (RBP4). Current and emerging therapies for TTR amyloid cardiomyopathy (ATTR-CM), including RNAi therapies and potentially CRISPR-based therapies, reduce hepatic transthyretin production and hence decrease serum RBP4, which decreases circulating vitamin A levels. However, despite these reductions in circulating vitamin A, hepatic reserves and alternative delivery mechanisms may prevent clinical manifestations of vitamin A deficiency. Vitamin A functions as a key regulator of immunity, antioxidant function, cell growth and differentiation and vision. This paper aims to serve as a comprehensive review of vitamin A and its metabolites, their transport, and their function in human health and disease. Additionally, we seek to synthesize the relevant outcomes and safety data of TTR silencing therapies and how they relate to circulating vitamin A levels and vitamin A-related clinical outcomes in a manner that is relevant to the cardiac amyloidosis specialist.